The European Biotech Act 2026: A Catalyst for Competitiveness and Innovation in Health Biotechnology

The biotechnology sector is rapidly emerging as a cornerstone of public health, economic resilience, and industrial competitiveness. From mRNA vaccines and gene therapies for rare diseases to bio-artificial skin for burn victims, health biotechnologies are fundamentally transforming patient care. Recognizing this immense potential, and the urgent need to keep pace with global competitors like the United States and China, the European Commission proposed a comprehensive package of measures in December 2025.

At the heart of this package is the European Biotech Act (2025/0406(COD)), a legislative framework designed to turbocharge the EU's health biotechnology and biomanufacturing sectors. This in-depth article details the context of the Act, its core provisions, what industry stakeholders can expect, and the various institutional perspectives shaping its future.

1. Context: The Need for European Action

While biotechnology is one of the fastest-growing economic sectors in the European Union, growing more than twice as fast as the overall EU economy over the last decade and generating over 900,000 jobs, the EU faces significant structural challenges.

According to a 2024 report by the Vlaams Instituut voor Biotechnologie, 66 out of 67 EU biotechnology companies that went public over the preceding six years chose to list on non-EU stock exchanges. Furthermore, the European Economic Area's (EEA) global share in commercial clinical trials halved from 22% in 2013 to just 12% in 2023, while China's share tripled. The root causes of this competitive disadvantage include:

• Regulatory fragmentation and lengthy approval procedures: The EU averages 113 days for multinational clinical trial approvals, compared to just 60 days in the US and China.
• A lack of late-stage risk capital and scale-up funding.
• Skills shortages and limited biomanufacturing capacities.

To address these vulnerabilities, the European Biotech Act was proposed as a flagship initiative of the 2025 Competitiveness Compass, translating the priorities of the highly influential Mario Draghi report into concrete actions.

2. Core Objectives of the Biotech Act

The proposed regulation applies to health biotechnology products and services across their entire lifecycle (research, funding, development, testing, validation, manufacturing, and marketing). Its primary objectives are threefold:

1. Improve the Internal Market: Establish an EU-level framework that strengthens the competitiveness of the health biotechnology sector from research to production.
2. Facilitate Innovation and Market Access: Create conditions that accelerate the development and timely placing of biotechnology innovations on the EU market.
3. Uphold High Standards: Maintain uncompromising standards for human and animal health, environmental protection, ethics, food safety, and biosecurity.

3. What to Expect: Key Provisions in Detail

The European Biotech Act introduces a wide array of measures to support innovation, boost funding, and ensure safety. Here is a detailed breakdown of what the industry can expect:

A. Regulatory Simplification and Acceleration

• Faster Clinical Trials: The Act introduces measures to significantly shorten timelines for cross-border clinical trial approvals.
• Regulatory Sandboxes: Companies will have access to "regulatory sandboxes" controlled environments allowing them to test innovative biotech technologies and products at a pre-market stage without bearing the full burden of standard regulations.
• Exemptions for GMO ATMPs: The Act proposes a risk-proportionate exemption from environmental risk assessments for Advanced Therapy Medicinal Products (ATMPs) containing Genetically Modified Organisms (GMOs) during clinical trials, provided they pose negligible risks to health and the environment.

B. Strategic Projects and Support Networks

• Health Biotechnology Strategic Projects: Projects making a substantial contribution to key policy areas (or displaying high cross-border relevance) can be designated as "strategic projects." These will qualify for fast-tracked administrative support, targeted scientific assistance, and facilitated access to EU funding.
• EU Health Biotechnology Support Network: A network of national and regional contact points will be established to assist developers, especially SMEs and start-ups, in navigating rules, identifying funding, and scaling up.

C. Incentives for EU-Based Manufacturing

To boost biomanufacturing capacity and ensure supply resilience within the EU, the Act offers highly targeted incentives:

• 12-Month SPC Extension: Developers of medicinal products created via biotechnology processes (and ATMPs) can receive a 12-month extension on their Supplementary Protection Certificates (SPCs).
• Conditions for SPC Extension: To qualify, the product must contain a uniquely new active substance, offer safety/efficacy equivalent to existing treatments, conduct clinical trials in more than two Member States, and crucially, perform at least one manufacturing step within the Union.

D. Investment and Access to Capital

• EU Health Biotechnology Investment Pilot: Created in cooperation with the European Investment Bank Group (EIBG), this initial two-year facility aims to bridge the investment gap related to scale-up and commercial manufacturing, keeping successful European start-ups from fleeing to overseas markets for late-stage capital.

E. Biosafety, Biosecurity, and Ethical Safeguards

• Misuse Prevention: The Act mandates stringent verifications for buyers of biotechnology products with high misuse potential (e.g., DNA sequences of dangerous pathogens).
• Biodefence Capabilities: It strengthens sequence screening obligations for service providers and improves early detection systems for novel biological threats.

4. Institutional and Industry Perspectives

The path to passing the European Biotech Act has generated significant discourse among EU institutions and industry stakeholders.

European Parliament and Council

In July 2025, the European Parliament overwhelmingly adopted a resolution endorsing a comprehensive Biotech Act, stressing the need to scale up R&D, integrate AI, and support SMEs to achieve strategic autonomy. The Council similarly called for a forward-looking framework to reduce regulatory complexity and cut red tape in its May and September 2025 conclusions.

Industry Feedback

Industry coalitions, including EuropaBio and the European Federation of Pharmaceutical Industries and Associations (EFPIA), have strongly welcomed the Act as a necessary step to make the regulatory environment more predictable. EuropaBio emphasized three pillars: faster financing, simpler EU legislation, and stronger global value chains.

However, organizations like the European Biosolutions Coalition have expressed concerns regarding the Act's primary focus on health. They argue for a broader scope that encompasses industrial, environmental, and agricultural biotech to ensure holistic green growth.

Civil Society

Civil society and NGOs have raised important points regarding the ethical implications and potential risks associated with GMO deregulation, urging that safety and affordability remain paramount alongside innovation.

5. Looking Ahead: The Two-Part Strategy

After lengthy discussions, the European Commission decided to split the biotech legislation into two distinct acts.

1. The First Act (Current Proposal): Focuses specifically on strengthening health biotechnology and streamlining food safety simplifications.
2. The Second Act (Expected Late 2026): Will center on industrial biotechnologies and broader biomanufacturing across all sectors, creating a cross-cutting regulatory environment conducive to broader bioeconomy innovations.

The European Biotech Act represents a defining moment for the EU's life sciences sector. By demanding that public investment yields tangible public benefits, through retained intellectual property, local manufacturing, and rapid patient access, the EU is attempting to reclaim its position as a premier global hub for biotechnology.